Literature DB >> 12537060

Minimally invasive orbital decompression for Graves' ophthalmopathy.

Marmar Vaseghi1, Thomas T Tarin, Peter S Levin, David J Terris.   

Abstract

We reviewed a 7-year experience at a tertiary-care, academic medical center with balanced, minimally invasive decompression for Graves' ophthalmopathy, in an effort to define the goals, risks, and outcomes of surgical intervention. Endoscopic medial decompression was performed in 26 patients; 23 underwent lateral decompression as well, and 13 also had inferior decompression. Septoplasty, turbinate reduction, and orbital rim augmentation were performed as needed. The indications for surgery were threat to vision (n = 10) and proptosis with a desire to return to the predisease state (rehabilitative, n = 16). The exophthalmos improved by a mean of 4.4 mm (p < .001). All patients who had surgery for threatened vision had improved vision after the operation. There were 3 patients with new-onset postoperative diplopia, 2 of whom underwent strabismus surgery. There was 1 case of postoperative sinusitis, which resolved with oral antibiotics and nasal decongestion, and 1 case of transient ulnar neuropathy. There were no other intraoperative or postoperative complications. Modern methods of orbital decompression provide a minimally invasive, effective, and relatively safe approach to the treatment of Graves' ophthalmopathy.

Entities:  

Mesh:

Year:  2003        PMID: 12537060     DOI: 10.1177/000348940311200112

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  2 in total

Review 1.  Sinus surgery: indications and techniques.

Authors:  Amber Luong; Bradley F Marple
Journal:  Clin Rev Allergy Immunol       Date:  2006-06       Impact factor: 8.667

Review 2.  Surgical complications in orbital decompression for Graves' orbitopathy.

Authors:  S Sellari-Franceschini; I Dallan; A Bajraktari; G Fiacchini; M Nardi; R Rocchi; C Marcocci; M Marinò; A P Casani
Journal:  Acta Otorhinolaryngol Ital       Date:  2016-08       Impact factor: 2.124

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.